Open House - Global Healthcare 2022: Imagion Biosystems | Edison Group
Imagion Biosystems Limited manufactures and supplies medical equipment. The Company offers a bio-imaging detection technology that uses disease specific targeting nanoparticles and highly sensitive detectors to locate tumors and other diseased cells by their molecular signature.
-
Bob Proulx, CEO, Imagion Biosystems
Bob has been President of Imagion Biosystems since February 2015 and led the company through the 2017 IPO on the Australian Securities Exchange (ASX:IBX). Bob’s career spans broad commercial experience in the computer, life science and medical diagnostics industries, e.g. President of Silicon Biosystems, Inc., Vice President Marketing and Sales for Nanogen, Inc., Senior Vice President of Marketing and Business Development at Gene Logic, and General Manager, Life Sciences at IGEN International, Inc. Mr. Proulx holds an M.A. and B.A. from The State University of New York at Albany and an Executive MBA from the Penn State Smeal College of Business.